logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Mega-trials and management of acute myocardial infarction.

    Article - En anglais

    Clinical management of acute myocardial infarction has been strongly influenced by large, simple trials (mega-trials) with unrestrictive protocols and limited data collection.

    The design has been adopted to increase statistical power to a maximum.

    Its validity rests on an effective randomisation procedure and intention-to-treat analysis of deaths.

    Experience has shown that mega-trials tend to generate effect-estimates nearer the null than those from conventional trials or meta-analyses.

    When a small or absent observed treatment effect (or subgroup effect) in a mega-trial contrasts with the results of conventionally designed trials, it is necessary to assess both null bias and failure to increase the true treatment effect to a maximum in the mega-trial.

    Null bias will arise when the contrast between treatment and no-treatment, or between subgroups, is blunted either by non-protocol therapy or by inaccuracy of data, including misclassification between subgroups.

    Each is more likely with an unrestrictive design.

    To increase the true treatment effect to a maximum, trial conditions must be specified with insight into mechanism, dose-dependence, and time-dependence.

    The mega-trial design is therefore unsuited to an exploratory role.

    These issues are illustrated by the examples of nitrates, angiotensin-converting-enzyme inhibitors, and magnesium in acute myocardial infarction but have general relevance to the validity and generalisability of simple trials.

    Mots-clés Pascal : Appareil circulatoire pathologie, Cardiopathie coronaire, Traitement, Homme, Infarctus, Myocarde, Essai thérapeutique contrôlé, Méthodologie, Royaume Uni, Europe, Myocarde pathologie

    Mots-clés Pascal anglais : Cardiovascular disease, Coronary heart disease, Treatment, Human, Infarct, Myocardium, Controlled therapeutic trial, Methodology, United Kingdom, Europe, Myocardial disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0516430

    Code Inist : 002B12A03. Création : 01/03/1996.